Aquestive Therapeutics, Inc. (AQST) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Aquestive Therapeutics, Inc. is a pharmaceutical company operating as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO). The company focuses on oral film delivery technologies, with key proprietary assets including Anaphylm (epinephrine sublingual film for anaphylaxis) and Libervant (diazepam buccal film for seizures). The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $14,446 | $8,720 |
| Net Loss | $(8,057) | $(22,930) |
| Loss Per Share (Basic & Diluted) | $(0.07) | $(0.24) |
| Cash and Cash Equivalents (End of Period) | $110,734 | $68,657 |
| Net Cash Used in Operating Activities | $(14,806) | $(23,400) |
| Total Debt (Notes Payable, Net) | $25,099 | $27,519 |
| Royalty Obligations, Net | $26,914 | $25,941 |
Revenue Composition (Q1 2026): Manufacture and supply ($8,793), License and royalty ($5,395), Co-development ($258). Proprietary product revenue was $0 due to the loss of U.S. market access for Libervant in April 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 66% year-over-year, driven primarily by a 583% increase in license and royalty revenue (due to a $4.5 million royalty recognition from Zevra related to the sale of Azstarys) and a 22% increase in manufacture and supply revenue.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 42% ($8.1 million), largely due to the absence of a one-time Anaphylm PDUFA fee ($4.3 million) and lower legal fees in the prior year period. R&D expenses decreased 22% due to lower clinical trial costs for Anaphylm.
- Improved Loss Profile: Net loss narrowed significantly from $22.9 million to $8.1 million, reflecting both revenue growth and cost management.
- Liquidity: Cash balance increased by approximately $42 million compared to the prior year period, supported by a $79.9 million underwritten public offering in August 2025 and ATM facility sales.
Guidance, Outlook, and Risks
Regulatory Status:
- Anaphylm: Received a Complete Response Letter (CRL) from the FDA on January 30, 2026, citing deficiencies in Human Factors (HF) validation (pouch opening and film placement). The company plans to conduct a new HF study and resubmit the NDA in Q3 2026. A Type A meeting with the FDA was held in March 2026.
- Libervant: U.S. market access for the 2-5 year age group was vacated by a District Court ruling in February 2025 due to Orphan Drug Exclusivity (ODE) disputes with Neurelis. The FDA converted approval to "tentative." The company is appealing and monitoring legislative changes to the Orphan Drug Act that may support market access prior to the ODE expiration in January 2027.
Capital Resources & Financing:
- The company expects to fund operations for at least the next 12 months using existing cash, ATM facility, and potential asset sales.
- Subsequent Event (May 12, 2026): Entered into a $150 million term loan facility with Oaktree Capital. The initial $55 million tranche was funded to repay the existing 13.5% Senior Secured Notes ($45 million principal).
- RTW Agreement: A $75 million purchase agreement with RTW Investments LP is contingent on FDA approval of Anaphylm and refinancing of debt.
Risks & Contingencies:
- Litigation: Ongoing product liability litigation regarding Suboxone (dental injuries) and securities class action lawsuits filed in March/April 2026 regarding Anaphylm disclosures.
- Customer Concentration: Indivior and Zevra represented approximately 57% and 32% of total revenue, respectively, in Q1 2026.
- Manufacturing: Reliance on third-party API suppliers and potential disruptions from geopolitical events.
Investor Verification Checklist
- Anaphylm Resubmission Timeline: Verify the status of the new Human Factors study and the confirmed Q3 2026 resubmission date following the FDA Type A meeting.
- Libervant Legal Outcome: Monitor the DC Appellate Court proceedings regarding the Neurelis lawsuit and the impact of recent Orphan Drug Act amendments on market access.
- Debt Refinancing Terms: Review the specific terms of the new Oaktree term loan facility (interest rates, covenants) compared to the redeemed 13.5% Notes.
- Securities Litigation: Assess the potential financial impact of the securities class action and shareholder derivative suits filed in Q2 2026.
- Suboxone Market Share: Monitor trends in Suboxone film market share as generic competition increases, given its status as a primary revenue driver.